First CAR-T approval (2017)
The FDA approved tisagenlecleucel, a CD19-directed CAR-T therapy, for children and young adults with B-cell acute lymphoblastic leukemia. It was the first gene therapy cleared in the United States.
The treatment produced high remission rates in patients with limited options.
The approval opened the way for CD19 CAR-T in lymphoma and, later, autoimmune disease.
Miv-cel uses the same CD19 target, but its goal is to wipe out antibody-making B cells rather than cancer cells.
